Transcatheter Valve Replacement for Tricuspid Regurgitation

(TRIPLACE Trial)

This trial aims to understand the safety and effectiveness of transcatheter tricuspid valve replacement (TTVR) for individuals with tricuspid regurgitation, a condition where the heart’s tricuspid valve doesn't close tightly, causing blood to flow backward. Researchers seek to identify which patients might face complications, such as needing a pacemaker, and how to best manage these situations. This trial is for those diagnosed with significant tricuspid valve issues who require the TTVR procedure. As a Phase 3 trial, it represents the final step before FDA approval, offering participants the opportunity to contribute to a potentially groundbreaking treatment.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that Transcatheter Tricuspid Valve Replacement (TTVR) is generally well-tolerated by patients. One study found that TTVR was successfully performed in 94% of cases. The in-hospital death rate was low at 1.37%, and the 30-day death rate was only 2.49%. Serious issues were rare, with only 1.7% of patients experiencing major problems within the first 30 days. After one year, this rate increased to 12.7%.

Unlike the standard of care for tricuspid regurgitation, which often involves open-heart surgery to repair or replace the valve, transcatheter tricuspid valve replacement (TTVR) is a minimally invasive alternative. Researchers are excited about TTVR because it doesn't require opening the chest, significantly reducing recovery time and risk for patients who might not be candidates for surgery. This approach uses catheters to replace the valve through blood vessels, offering a promising option for patients with severe symptoms who need a less invasive solution.

Studies have shown that Transcatheter Tricuspid Valve Replacement (TTVR), which participants in this trial will undergo, can greatly reduce tricuspid regurgitation, a condition where the heart's tricuspid valve leaks. Research indicates that the procedure succeeds 94% of the time. Patients often experience improved well-being and a higher quality of life after the treatment. Additionally, TTVR is associated with low mortality rates both in the hospital and 30 days post-procedure. Long-term results also demonstrate better survival rates compared to other treatments.¹²⁵⁶⁷